Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.57 |
| ▸ | HTR3B | O95264 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912678 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1HTR3EHTR3BCYP1A2 | |
| SCHEMBL3969056 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1HTR3EHTR3BCYP1A2 | |
| SCHEMBL5912806 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1HTR3EHTR3BCYP1A2 | |
| SCHEMBL15589509 | 0.83 | HTR3A (0.51) | KDM4EALDH1A1HTR3AHTTHRH4 | |
| SCHEMBL14305157 | 0.83 | HTR3A (0.51) | KDM4EALDH1A1HTR3AHTTHRH4 | |
| SCHEMBL15589508 | 0.83 | HTR3A (0.51) | KDM4EALDH1A1HTR3AHTTHRH4 | |
| SCHEMBL15589488 | 0.81 | PRKCQ (0.61) | PRKCQPRKCDHDAC1 | |
| SCHEMBL4779583 | 0.80 | HTR3A (0.52) | HTR3AHTTHRH4PRKCQPRKCD | |
| SCHEMBL15543168 | 0.78 | PRKCQ (0.47) | HTR3AHTTPRKCQPRKCDHDAC1 | |
| SCHEMBL15589492 | 0.77 | PRKCQ (0.54) | PRKCQPRKCDHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| EP-2867221-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | KDM4E 3688/4885ALDH1A1 3960/4885HTR3E 4300/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | KDM4E 3291/4885ALDH1A1 4019/4885HTR3E 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.